IDEAYA Biosciences stock reports Q2 revenue growth despite loss

Published on 10/01/2026 at 02:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IDEAYA Biosciences stock reflects a Q2 loss of USD 1.22 per share after August 4 results. The average analyst target was USD 52.46, while Michael White became R&D president on September 28, 2026.

IDYA, US45166A1025, Illustration mit AI erstellt.

IDEAYA Biosciences (ISIN US45166A1025) reported USD 8.86 million in second-quarter 2026 revenue, above the USD 8.02 million analyst consensus cited for the August 4 results. The company also posted a loss of USD 1.22 per share, missing the USD 1.06 consensus estimate, according to MarketBeat. The numbers leave revenue as the stronger part of the latest quarterly picture, while the earnings shortfall remains the key counterweight.

Revenue clears the consensus

The USD 8.86 million revenue result exceeded expectations by USD 0.84 million, a quantified comparison that matters more than the companys headline growth profile for near-term valuation. The quarterly loss, however, was USD 0.16 per share wider than the USD 1.06 consensus estimate, showing that commercial progress has not yet translated into earnings.

IDEAYA is a clinical-stage biotechnology company developing precision oncology therapies for genetically defined cancers. Its pipeline includes darovasertib, also known as IDE196, a protein kinase C inhibitor being studied in uveal melanoma and other solid tumors.

Pipeline leadership changes

IDEAYA announced on September 28, 2026, that Michael White would become president of research and development after serving as chief scientific officer since 2021. PR Newswire reported that the expanded role will cover continued development of IDEAYA's precision oncology pipeline, including programs for uveal melanoma, pancreatic cancer and lung cancer.

The leadership move comes as analysts maintain a positive but divided view. MarketBeat reported a Moderate Buy consensus from 15 firms, including 13 Buy ratings, one Hold and one Sell, with an average 12-month price target of USD 52.46.

Prior close was EUR 33.91

The Lang & Schwarz prior close was EUR 33.91 on September 29, 2026. The quote timestamp was September 30, 2026 at 10:59 p.m. CEST. IDEAYA Biosciences is listed on NASDAQ under ticker IDYA, and the company operates in the Healthcare sector and Biotechnology industry.